Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 13 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 28 patents granted in the last 365 days
Translate Bio Inc. manages a portfolio with 18 pending office actions primarily located in the Biotechnology & Pharmaceuticals technology area. This volume of activity is spread across 17 distinct examiners and 14 distinct art units. Such a wide distribution indicates a diverse range of pharmaceutical technologies and requires the company to manage various examiner styles and art unit standards concurrently. The high number of 17 distinct examiners relative to the total actions suggests that almost every pending matter is being reviewed by a different individual.
The busiest examiner, POPA, ILEANA, is responsible for 2 pending office actions. This represents a portion of the 18 total actions, highlighting that the portfolio is not overly dependent on any single individual at the patent office. The presence of 14 distinct art units suggests that the company's research and development efforts span across many specialized sub-fields within the broader biotechnology sector. Practitioners must be prepared for a decentralized prosecution process given the variety of art units involved.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 4 (24%) |
| §112 only | 2 (12%) |
| Double-patenting only | 2 (12%) |
| Double-patenting + other | 3 (18%) |
| Multi-statute (no §101) | 5 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 2 | 21.4% | +15.1% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
| GROSS, CHRISTOPHER M | 1 | 63.5% | +40.2% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| HANEY, AMANDA MARIE | 1 | 36.4% | +44.9% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| MOORE, JOHN DAVID | 1 | 64.2% | +24.8% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
| POHNERT, STEVEN C | 1 | 12.4% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 9d |
| 17534956 | Stable Liquid Lipid Nanoparticle Formulations | MITCHELL, EDWIN COLEMAN | 47d |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | GROSS, CHRISTOPHER M | — |
| 18552165 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | MOORE, JOHN DAVID | — |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SINGH, ANOOP KUMAR | — |
| 18065952 | LARGE-SCALE SYNTHESIS OF MESSENGER RNA | POHNERT, STEVEN C | — |
| 17262421 | Dry Powder Formulations for Messenger RNA | HAGHIGHATIAN, MINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246263 | PIPERAZINE-BASED CATIONIC LIPIDS | ANDERSON, REBECCA L | 18d overdue |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 9d |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18815955 | Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle | JONES, DAMERON LEVEST | — |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | GROSS, CHRISTOPHER M | — |
| 18565849 | ASSAY FOR QUANTITATIVE ASSESSMENT OF MRNA CAPPING EFFICIENCY | GROOMS, TIFFANY NICOLE | — |
| 18557446 | METHODS FOR MEASURING POLY A TAIL LENGTH | HANEY, AMANDA MARIE | — |
| 18286029 | IMPROVED COMPOSITIONS FOR DELIVERY OF MRNA | ZARA, JANE J | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1683 | 2 |
| 1618 | 1 |
| 1693 | 1 |
| 1656 | 1 |
| 1626 | 1 |
| 1632 | 1 |
| 1611 | 1 |
| 1634 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — | §101§103§112Other | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18815955 | Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle | JONES, DAMERON LEVEST | 1618 | DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | GROSS, CHRISTOPHER M | — | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18565849 | ASSAY FOR QUANTITATIVE ASSESSMENT OF MRNA CAPPING EFFICIENCY | GROOMS, TIFFANY NICOLE | 1637 | §112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18557446 | METHODS FOR MEASURING POLY A TAIL LENGTH | HANEY, AMANDA MARIE | 1693 | §103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18286029 | IMPROVED COMPOSITIONS FOR DELIVERY OF MRNA | ZARA, JANE J | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18552165 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | MOORE, JOHN DAVID | 1656 | §103§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18246263 | PIPERAZINE-BASED CATIONIC LIPIDS | ANDERSON, REBECCA L | 1626 | DP | Final Rejection | 18d overdue | Pending | Mar 22, 2023 |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2023 |
| 18065952 | LARGE-SCALE SYNTHESIS OF MESSENGER RNA | POHNERT, STEVEN C | 1683 | §103§112DP | Final Rejection | — | Pending | Dec 14, 2022 |
| 17786971 | RECTAL DELIVERY OF MESSENGER RNA | KAMM, JUDITH MARIE | 1611 | §103 | Non-Final OA | — | Pending | Jun 17, 2022 |
| 17631322 | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | CONNORS, ALEXANDRA F | 1634 | §112Other | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17534956 | Stable Liquid Lipid Nanoparticle Formulations | MITCHELL, EDWIN COLEMAN | 1619 | §103§112Other | Non-Final OA | 47d | Pending | Nov 24, 2021 |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 1633 | §103Other | Non-Final OA | 9d | Pending | Oct 12, 2021 |
| 17472622 | COMPOSITIONS AND METHODS FOR mRNA DELIVERY | KIM, TAEYOON | 1631 | §103 | Final Rejection | — | Pending | Sep 11, 2021 |
| 17344535 | METHODS FOR PURIFICATION OF MESSENGER RNA | LU, FRANK WEI MIN | 1683 | §103§112DP | Non-Final OA | — | Pending | Jun 10, 2021 |
| 17262421 | Dry Powder Formulations for Messenger RNA | HAGHIGHATIAN, MINA | 1616 | §103§112 | Non-Final OA | — | Pending | Jan 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial